Daiken Biomedical Co., Ltd. (TPE:7780)
Taiwan · Delayed Price · Currency is TWD 16.95
-0.10 (-0.59%)
At close: Aug 28, 2026
Daiken Biomedical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| 2,186 | 1,895 | 1,362 | 1,190 | 884.97 | |
Revenue Growth | 34.28% | 39.10% | 14.45% | 34.52% | - |
Cost of Revenue | 835.12 | 689.36 | 506.17 | 376.66 | 271.66 |
Gross Profit | 1,351 | 1,206 | 856.22 | 813.76 | 613.3 |
Selling, General & Admin | 945.3 | 906.21 | 696.26 | 601.78 | 493.5 |
Research & Development | 11.28 | 11.28 | 10.16 | 7.82 | 7.36 |
Operating Expenses | 956.6 | 917.52 | 707.3 | 609.61 | 500.87 |
Operating Income | 393.91 | 288.21 | 148.92 | 204.15 | 112.44 |
Interest Expense | -2.05 | -0.6 | -6 | -3.36 | -1.18 |
Interest & Investment Income | 109.51 | 32.89 | 28.43 | 2.87 | 0.2 |
Currency Exchange Gain (Loss) | 46.53 | 7.28 | -31.85 | -8.39 | -1.92 |
Other Non Operating Income (Expenses) | 0.81 | 89.69 | 0.11 | 0.08 | 0.01 |
Pretax Income | 548.72 | 417.48 | 139.6 | 195.35 | 109.54 |
Income Tax Expense | 123.76 | 79.62 | 33.02 | 35 | 19.36 |
Net Income | 424.96 | 337.87 | 106.58 | 160.35 | 90.17 |
Net Income to Common | 424.96 | 337.87 | 106.58 | 160.35 | 90.17 |
Net Income Growth | 72.08% | 217.01% | -33.53% | 77.83% | - |
Shares Outstanding (Basic) | 772 | 667 | 439 | 224 | 155 |
Shares Outstanding (Diluted) | 772 | 668 | 439 | 225 | 156 |
Shares Change | 28.50% | 52.12% | 95.20% | 44.34% | - |
EPS (Basic) | 0.55 | 0.51 | 0.24 | 0.72 | 0.58 |
EPS (Diluted) | 0.55 | 0.51 | 0.24 | 0.71 | 0.58 |
EPS Growth | 34.45% | 110.95% | -66.34% | 23.14% | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Free Cash Flow | 261.89 | 272.21 | 50.5 | 105.21 | 41.58 |
Free Cash Flow Per Share | 0.34 | 0.41 | 0.12 | 0.47 | 0.27 |
Dividend Per Share | 0.495 | 0.698 | 0.404 | 0.486 | 0.417 |
Dividend Growth | -42.65% | 72.88% | -16.87% | 16.55% | - |
Gross Margin | 61.79% | 63.62% | 62.85% | 68.36% | 69.30% |
Operating Margin | 18.02% | 15.21% | 10.93% | 17.15% | 12.71% |
Profit Margin | 19.44% | 17.83% | 7.82% | 13.47% | 10.19% |
Free Cash Flow Margin | 11.98% | 14.36% | 3.71% | 8.84% | 4.70% |
EBITDA | 400.99 | 295.16 | 153.13 | 205.07 | 112.54 |
EBITDA Margin | 18.35% | 15.57% | 11.24% | 17.23% | 12.72% |
D&A For EBITDA | 7.09 | 6.95 | 4.21 | 0.92 | 0.1 |
EBIT | 393.91 | 288.21 | 148.92 | 204.15 | 112.44 |
EBIT Margin | 18.02% | 15.21% | 10.93% | 17.15% | 12.71% |
Effective Tax Rate | 22.55% | 19.07% | 23.65% | 17.91% | 17.68% |
Advertising Expenses | - | 450.14 | 380.08 | 383.45 | 329.81 |